Premium
Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain
Author(s) -
Civeira J.,
Cervera S.,
Giner J.,
Allen S. R.,
Hellstern K.,
Malanowski H.,
Wirz R.,
Klär K.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05327.x
Subject(s) - moclobemide , clomipramine , tolerability , medicine , adverse effect , randomized controlled trial , depression (economics) , antidepressant , anesthesia , psychology , macroeconomics , hippocampus , economics
The efficacy, tolerability and safety of moclobemide were compared with those of clomipramine in a double‐blind, randomized parallel group study over 4 weeks. Patients were suffering from various forms of depression: 33 received moclobemide and 31 clomipramine. The mean score on the Hamilton Rating Scale for Depression decreased gradually in both groups, with no significant differences between them; the final scores showed an improvement of 57% in the moclobemide group and 60% in the clomipramine group, compared with baseline. The investigators’ assessment of efficacy at the end of treatment was good or very good for 60% of moclobemide patients and 50% of clomipramine patients, and tolerance was good or very good for 31 patients on moclobemide and 26 on clomipramine. The drugs thus showed comparable antidepressant efficacy, and both were mostly well tolerated, although adverse events were more prevalent in patients treated with clomipramine.